Literature DB >> 18725649

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.

Shaheenah Dawood1, Kristine Broglio, Ana M Gonzalez-Angulo, Aman U Buzdar, Gabriel N Hortobagyi, Sharon H Giordano.   

Abstract

PURPOSE: Overall, breast cancer mortality has been declining in the United States, but survival studies of patients with stage IV disease are limited. The aim of this study was to evaluate trends in and factors affecting survival in a large population-based cohort of patients with newly diagnosed stage IV breast cancer. PATIENTS AND METHODS: We searched the Surveillance, Epidemiology, and End Results registry to identify female patients with stage IV breast cancer diagnosed between 1988 and 2003. Patients were divided into three groups according to year of diagnosis (1988 to 1993, 1994 to 1998, and 1999 to 2003). Survival outcomes were estimated by the Kaplan-Meier method, and Cox models were fit to determine the characteristics independently associated with survival.
RESULTS: We identified 15,438 patients. Median age was 62 years. Median follow-up was 16 months, 18 months, and 11 months in periods 1988 to 1993, 1994 to 1998, and 1999 to 2003, respectively. Median breast cancer-specific survival was 23 months. In the multivariate model, earlier year of diagnosis, grade 3 disease, increasing age, being unmarried, hormone receptor-negative disease, and no surgery were all independently associated with worse overall and breast cancer-specific survival. With each successive year of diagnosis, black patients had an increasingly greater risk of death compared with white patients (hazard ratio, 1.03; 95% CI, 1.00 to 1.06; P = .031).
CONCLUSION: The survival of patients with newly diagnosed stage IV breast cancer has modestly improved over time, but these data suggest that the disparity in survival between black and white patients has increased.

Entities:  

Mesh:

Year:  2008        PMID: 18725649      PMCID: PMC2736998          DOI: 10.1200/JCO.2007.14.1168

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.

Authors:  Gildy V Babiera; Roshni Rao; Lei Feng; Funda Meric-Bernstam; Henry M Kuerer; S Eva Singletary; Kelly K Hunt; Merrick I Ross; Karin M Gwyn; Barry W Feig; Frederick C Ames; Gabriel N Hortobagyi
Journal:  Ann Surg Oncol       Date:  2006-04-17       Impact factor: 5.344

2.  Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.

Authors:  Lisa A Newman; Kent A Griffith; Ismail Jatoi; Michael S Simon; Joseph P Crowe; Graham A Colditz
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

3.  Racial differences in mortality from obesity-related chronic diseases in US women diagnosed with breast cancer.

Authors:  Anthony P Polednak
Journal:  Ethn Dis       Date:  2004       Impact factor: 1.847

4.  Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research.

Authors:  A B Nattinger; T L McAuliffe; M M Schapira
Journal:  J Clin Epidemiol       Date:  1997-08       Impact factor: 6.437

5.  Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer.

Authors:  B A Jones; S V Kasi; M G Curnen; P H Owens; R Dubrow
Journal:  Am J Epidemiol       Date:  1997-09-01       Impact factor: 4.897

6.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome.

Authors:  Rowan T Chlebowski; Zhao Chen; Garnet L Anderson; Thomas Rohan; Aaron Aragaki; Dorothy Lane; Nancy C Dolan; Electra D Paskett; Anne McTiernan; F Alan Hubbell; Lucile L Adams-Campbell; Ross Prentice
Journal:  J Natl Cancer Inst       Date:  2005-03-16       Impact factor: 13.506

7.  Comorbidity and survival disparities among black and white patients with breast cancer.

Authors:  C Martin Tammemagi; David Nerenz; Christine Neslund-Dudas; Carolyn Feldkamp; David Nathanson
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

8.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

9.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

View more
  73 in total

1.  Understanding health-related quality of life in adult women with metastatic cancer who have dependent children.

Authors:  Eliza M Park; Allison M Deal; Justin M Yopp; Teresa Edwards; Samuel J Resnick; Mi-Kyung Song; Zev M Nakamura; Donald L Rosenstein
Journal:  Cancer       Date:  2018-05-06       Impact factor: 6.860

2.  Survival after recurrence of stage I-III breast, colorectal, or lung cancer.

Authors:  Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Paul Fishman; Debra P Ritzwoller
Journal:  Cancer Epidemiol       Date:  2017-07-12       Impact factor: 2.984

3.  Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.

Authors:  Claudine Isaacs; Pia Herbolsheimer; Minetta C Liu; Mary Wilkinson; Yvonne Ottaviano; Gina G Chung; Robert Warren; Jennifer Eng-Wong; Philip Cohen; Karen L Smith; Karen Creswell; Antonella Novielli; Rebecca Slack
Journal:  Breast Cancer Res Treat       Date:  2010-10-26       Impact factor: 4.872

4.  Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer.

Authors:  Yoshimasa Kosaka; Naoko Minatani; Yoko Tanaka; Akiko Shida; Mariko Kikuchi; Hiroshi Nishimiya; Mina Waraya; Hiroshi Katoh; Takeo Sato; Norihiko Sengoku; Hirokazu Tanino; Keishi Yamashita; Masahiko Watanabe
Journal:  Mol Clin Oncol       Date:  2018-09-13

5.  Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.

Authors:  Raffaella Palumbo; Federico Sottotetti; Alberto Riccardi; Cristina Teragni; Emma Pozzi; Erica Quaquarini; Barbara Tagliaferri; Antonio Bernardo
Journal:  Ther Adv Med Oncol       Date:  2013-11       Impact factor: 8.168

6.  African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.

Authors:  Ani Balmanoukian; Zhe Zhang; Stacie Jeter; Shannon Slater; Deborah K Armstrong; Leisha A Emens; John H Fetting; Antonio C Wolff; Nancy E Davidson; Lisa Jacobs; Julie Lange; Theodore N Tsangaris; Richard Zellars; Edward Gabrielson; Vered Stearns
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

Review 7.  Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Virginia G Kaklamani; William J Gradishar
Journal:  Oncologist       Date:  2017-03-17

8.  Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.

Authors:  Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Nadia Harbeck; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-20       Impact factor: 4.553

9.  Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.

Authors:  Amye J Tevaarwerk; Robert J Gray; Bryan P Schneider; Mary Lou Smith; Lynne I Wagner; John H Fetting; Nancy Davidson; Lori J Goldstein; Kathy D Miller; Joseph A Sparano
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

10.  Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.

Authors:  Eleni Andreopoulou; Joseph A Sparano
Journal:  Curr Breast Cancer Rep       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.